Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Adaptimmune logo — Designing and delivering cell therapies to transform the liv...

Adaptimmune

Designing and delivering cell therapies to transform the lives of people with cancer.

Founded 2008 United Kingdom Abingdon, United Kingdom 200 employees Post Ipo Debt Total: $499.50M Biopharma, Biotechnology +1

General Information

Company Name Adaptimmune
Founded Year 2008
Location United Kingdom Abingdon, United Kingdom +3
Founders / Decision Makers
Team member Team member
Employees 200
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post Ipo Debt
Social

Get notified when Adaptimmune moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Adaptimmune

Adaptimmune stands as a pioneering entity in the biopharmaceutical landscape, specializing in cell therapies designed to revolutionize cancer treatment. With its strong presence in four biotechnology hubs across the U.K. and U.S., the company showcases comprehensive competencies ranging from preclinical research to commercial operations.

Founded in 2008, Adaptimmune has established itself as a significant player in the Biopharma, Biotechnology, and Health Care sectors. The recent financial endorsement came as a $25.00M Post-IPO Debt investment on May 15, 2024, led by Hercules Capital, underscoring investor confidence in their innovative capabilities.

As Adaptimmune advances its groundbreaking cell therapy solutions, it remains an attractive prospect for venture capitalists interested in companies with strong growth potential and transformative technologies in oncology.

Taxonomy: Cell Therapy, Cancer Treatment, T Cell Therapies, Preclinical Research, Clinical Development, Translational Sciences, Autologous Manufacturing, Allogeneic Manufacturing, T Cell Receptor Proteins, Affinity T Cell Receptor, Immunotherapy, Infectious Disease Treatment, HIV Therapy, Corporate Operations

Services & Products

Development of T-cell therapies
Pipeline management of cell therapies
Sale and licensing of cell therapies
Biotechnological research
Clinical trials

Target Customers

Cancer patients Healthcare professionals Biopharmaceutical companies Medical researchers

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt •••••• 1
Investor
15 May 2024
Post-IPO Equity •••••• 1 •••• •••• 07 Sep 2021
Post-IPO Equity •••••• - 30 Aug 2019
Post-IPO Equity •••••• - 06 Sep 2018
Post-IPO Equity •••••• - 11 Apr 2017

View All 9 Funding Rounds

Adaptimmune Alternatives & Competitors

View All Alternatives
Adaptimmune vs
Olema Oncology
Olema Oncology United States

Post Ipo Equity
164 employees
Biopharma, Biotechnology
Compare Adaptimmune vs Olema Oncology
Adaptimmune vs
Legend Biotech
Legend Biotech United States

Multinational biopharmaceutical company focused on discovering and developing cutting-edge cell-base...

Unknown
2565 employees
Biotechnology, Health Care
Compare Adaptimmune vs Legend Biotech
Adaptimmune vs
Allogene Therapeutics
Allogene Therapeutics United States

A biotechnology company catalyzing cancer treatment through the development of CAR T therapy

IPO
214 employees
Biotechnology
Compare Adaptimmune vs Allogene Therapeutics
View all alternatives

FAQ About Adaptimmune

Designing and delivering cell therapies to transform the lives of people with cancer.
Adaptimmune was founded in 2008.
Adaptimmune is headquartered in Abingdon, United Kingdom.
Adaptimmune operates in the following industries: Biopharma, Biotechnology, Health Care.
Adaptimmune has approximately 200 employees.
Adaptimmune has completed 9 funding rounds, raising a total of $499.50M. The latest funding stage is Post Ipo Debt.
Adaptimmune offers: Development of T-cell therapies, Pipeline management of cell therapies, Sale and licensing of cell therapies, Biotechnological research, Clinical trials.
Top alternatives and competitors to Adaptimmune include Olema Oncology, Legend Biotech, Allogene Therapeutics, Vera Therapeutics, Inc., ADOCIA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Adaptimmune and Olema Oncology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Adaptimmune and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy